Cargando…

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

The past decade has brought substantial advances in the management of inflammatory bowel diseases (IBD). The introduction of tumor necrosis factor (TNF) antagonists, evidence for the value of combination therapy, the recognition of targeting lymphocyte trafficking and activation as a viable treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinglas, Jason, Gonczi, Lorant, Kurt, Zsuzsanna, Bessissow, Talat, Lakatos, Peter L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113721/ https://www.ncbi.nlm.nih.gov/pubmed/30166855 http://dx.doi.org/10.3748/wjg.v24.i32.3567

Ejemplares similares

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?
por: Gonczi, Lorant, et al.
Publicado: (2019)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
por: Verdon, Christine, et al.
Publicado: (2019)

Endoscopic management of Crohn’s strictures
por: Bessissow, Talat, et al.
Publicado: (2018)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
por: Lontai, Livia, et al.
Publicado: (2023)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Isolated Small Bowel Amyloidosis
por: Ghaith, Jenan, et al.
Publicado: (2021)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease
por: Restellini, Sophie, et al.
Publicado: (2017)

Therapeutic preferences and outcomes in newly diagnosed patients with Crohn’s diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database
por: Kurti, Zsuzsanna, et al.
Publicado: (2018)

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses
por: Strohl, Matthew, et al.
Publicado: (2017)

Adenocarcinoma Within Carpet-Like Pseudopolyposis
por: Xiao, Yasi, et al.
Publicado: (2020)

Biologic Therapies for the Treatment of Post-ileal Pouch Anal Anastomosis Surgery Chronic Inflammatory Disorders: Systematic Review and Meta-analysis
por: Shehab, Mohammad, et al.
Publicado: (2022)

Advances in the Diagnosis and Management of Inflammatory Bowel Disease: Challenges and Uncertainties
por: Mosli, Mahmoud, et al.
Publicado: (2014)

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
por: Balderramo, Domingo
Publicado: (2022)

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
por: Chao, Che-Yung, et al.
Publicado: (2016)

Small Molecule Drugs in Inflammatory Bowel Diseases
por: Ben Ghezala, Inès, et al.
Publicado: (2021)

Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies
por: Cheah, Eric, et al.
Publicado: (2023)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

Esophageal Squamous Cell Carcinoma With Colonic Metastases
por: Wiseman, Daniel, et al.
Publicado: (2020)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Hereditary Nonpolyposis Colorectal Cancer in Association with Crohn's Disease and Lynch Syndrome: The Importance of a Strict Endoscopic Surveillance
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Breaking the Therapeutic Ceiling: Dual Biologic or Small Molecule Therapy for Refractory Inflammatory Bowel Disease
por: Ahmed, Waseem
Publicado: (2022)

Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease
por: Xu, Yi-Han, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6u92tts0tp66n9a6rjbh9tgdq4